ARGX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Argenx SE (ARGX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. Despite recent price fluctuations, the strong analyst ratings, positive growth trajectory, and robust pipeline make it a compelling long-term investment opportunity.
The MACD histogram is positive at 14.346, indicating bullish momentum, though it is contracting. RSI is at 78.29, in the neutral zone, suggesting no immediate overbought or oversold conditions. Moving averages are converging, and the price is near the R1 resistance level of 837.101, showing potential for upward movement. Key support is at 748.779.
Strong analyst ratings with multiple firms maintaining Buy or Outperform ratings and high price targets.
Continued growth in Vyvgart sales and positive Phase 3 data in ocular myasthenia gravis.
Robust pipeline with 20 ongoing Phase II/III trials.
Goldman Sachs added Argenx to its European Conviction List, citing a compelling entry point.
Recent financials show a drop in net income (-31.16% YoY) and EPS (-30.98% YoY), which could weigh on short-term sentiment.
Gross margin slightly declined to 88.36%.
No significant hedge fund or insider trading trends to support bullish sentiment.
In Q4 2025, revenue increased by 74.12% YoY to $1.29B, showcasing strong top-line growth. However, net income dropped by 31.16% YoY to $532.95M, and EPS fell by 30.98% to 8.02. Gross margin also declined slightly to 88.36%, indicating some pressure on profitability.
Analysts are highly positive on Argenx. Oppenheimer, Goldman Sachs, Deutsche Bank, and others maintain Buy or Outperform ratings with price targets ranging from $725 to $1,247. Analysts highlight strong Vyvgart sales, a robust pipeline, and consistent profitability as key drivers.
